CONSTITUTION MEDICAL INVESTORS
Constitution Medical Investors, Inc. (CMI), based in Boston Massachusetts (USA). CMI is the developer of a highly innovative hematology testing system, which is designed to provide faster and more accurate diagnosis of blood-related diseases, thereby improving patient care. CMI was created and funded by the private equity firm Warburg Pincus and members of CMI’s management team.
CONSTITUTION MEDICAL INVESTORS
Industry:
Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.conmedinvestors.com
Total Employee:
11+
Status:
Closed
Contact:
6177265097
Email Addresses:
[email protected]
Total Funding:
48.35 M USD
Technology used in webpage:
SPF IPv6 MailChannels
Similar Organizations
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.conmedinvestors.com
Unable to get host informations!!!
More informations about "Constitution Medical Investors"
Constitution Medical Investors - Crunchbase Company Profile
Organization. Constitution Medical Investors . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email …See details»
Constitution Medical Investors - PitchBook
Constitution Medical Investors General Information Description. Provider of healthcare services. The company focuses on the identification and acquisition of healthcare platform technologies …See details»
Investor Relations - CONMED
You are about to be directed to a website maintained by another organization that is solely responsible for its content. As we cannot control the content, data security, or privacy practices …See details»
Constitution Medical Investors - Products, Competitors, Financials ...
Constitution Medical Investors is focused on pursuing investments in platform companies and technologies primarily within the in vitro diagnostics and medical device sectors, where the …See details»
Constitution Medical Investors, Inc - VentureRadar
Constitution Medical Investors, Inc VentureRadar profile. Find out more about Constitution Medical Investors, Inc including the VentureRadar Innovation and Growth scores, Similar …See details»
Executive Changes and Financial Highlights at CONMED Corporation
Sep 20, 2024 His departure is set for the end of September, marking a pivotal moment for the organization. Transitioning into the role of Interim Corporate Controller will be Kimberly A. …See details»
Conmed Company Profile 2024: Stock Performance & Earnings
Conmed Investors. Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info; This information is available in the PitchBook Platform. To explore Conmed‘s full …See details»
Investor Presentation - CONMED
Apr 26, 2023 Orthopedics: Large, Attractive Markets Q1 2023 Earnings Call 2022 74% Recurring, single-use revenue International 62% US 38% 5 Category Description Market Size …See details»
Annual Reports | Financial Information | Investor Relations
Jan 31, 2018 Financial Reports Title; Supplemental Financial Disclosures as of January 31, 2018 12.1 MBSee details»
Corporate Governance - CONMED
Council also serves on the global board of Girl Up, a UN Foundation Organization. The Board of Directors has determined that Ms. Council is independent within the meaning of the rules of …See details»
CONMED - Leadership Team - The Org
This team, comprising key executives in finance, operations, marketing, and human resources, collaborates to formulate policies, assess market opportunities, and foster a culture of …See details»
Exploring CONMED Corporation (CNMD) Investor Profile: Who’s …
As of Q3 2024, the company's financial performance supports investor interest, with a net income of $98.7 million for the nine months ended September 30, 2024, up from $31.4 million in the …See details»
HOLOGIC : Constitution Medical Investors, Inc., Led By Former …
BOSTON and NEW YORK, June 23 /PRNewswire/ -- Constitution Medical Investors, Inc. , a Boston-based private investment firm focused on healthcare sector-related acquisitions and …See details»
CONMED Company Profile | Management and Employees List
CONMED Profile and History. Founded in 1970, CONMED is a global medical technology company that specializes in the development and sale of surgical and patient monitoring …See details»
Company CONMED Corporation - MarketScreener.com
Jul 25, 2013 CONMED Corporation is a medical technology company, which provides surgical devices and equipment for minimally invasive procedures. Its products are used by surgeons …See details»
CONMED - Raised Funding from 4 investors - Tracxn
Nov 15, 2024 Building Radar - Munich based, raised a funding of $7.2M in Series A round held on 07 Oct, 2024.; Rebaza, Alcázar & De Las Casas - San Isidro based, raised a funding of …See details»
Breaking Down CONMED Corporation (CNMD) Financial Health: …
Single-use products accounted for a significant portion of total sales, with $270.8 million in Q3 2024, reflecting an increase of 6.9% from $253.3 million in Q3 2023. However, capital …See details»
Conmed Stock Ownership - Who Owns Conmed in 2024?
Name Role Date Shares Price Value; Richard Glaze: Chief Information Officer: 2024-11-20: 118: $70.69See details»
CONMED Corporation Announces First Quarter 2024 Financial …
LARGO, Fla., April 24, 2024--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024.. First Quarter 2024 …See details»
Conmed Corp (CNMD) Reports Record Revenue Growth and …
Feb 1, 2024 Revenue: Q4 2023 net sales reached $327.0 million, a 30.4% increase from Q4 2022.. Full-Year Revenue: 2023 net sales totaled $1.244 billion, up 19.1% from 2022.. Net …See details»